Starting from this observation, we investigated whether different modalities of drug exposure influenced the acquired resistance to EGFR-TKIs, using two EGFR-mutant NSCLC cell lines exposed to continuous or intermittent suboptimal doses of gefitinib until the acquisition of resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.